BPG is committed to discovery and dissemination of knowledge
Articles in Press
1/20/2022 5:19:03 AM | Browse: 102 | Download: 241
Category |
Gastroenterology & Hepatology |
Manuscript Type |
Basic Study |
Article Title |
Melatonin restores zinc levels, activates the Keap1/Nrf2 pathway, and modulates endoplasmic reticular stress and HSP in rats with chronic hepatotoxicity
|
Manuscript Source |
Invited Manuscript |
All Author List |
Silvia Bona, Sabrina Alves Fernandes, Andrea C Janz Moreira, Graziella Rodrigues, Elizângela G Schemitt, Fabio Cangeri Di Naso, Cláudio A Marroni and Norma P Marroni |
Funding Agency and Grant Number |
Funding Agency |
Grant Number |
FIPE/Hospital de Clínicas of Porto Alegre |
|
|
Corresponding Author |
Norma P Marroni, PhD, Doctor, Full Professor, Research Scientist, Medical Sciences Program, Universidade Federal do Rio Grande do Sul, Rua José Kanan Aranha 102, Porto Alegre 90040-060, RS, Brazil. nmarroni@terra.com.br |
Key Words |
Liver injury; Cell damage; Antioxidant; Melatonin; Carbon tetrachloride |
Core Tip |
Liver cirrhosis is a chronic condition of the liver that is characterized by inflammation, steatosis, and formation of fibrotic tissue that impair liver function. Several studies have demonstrated the relationship between oxidative stress and the development of different diseases. As oxidative stress can damage lipids, proteins, and DNA, causing changes in cell homeostasis, it is important to study therapeutic substances that can minimize or delay the effects of the disease. Hepatotoxic drugs are commonly used as an experimental model to assess different stages of liver disease. Melatonin was used in this work as a therapeutic strategy and showed hepatoprotective action in a chronic hepatotoxicity model. |
Citation |
Bona S, Fernandes SA, Moreira ACJ, Rodrigues G, Schemitt EG, Di Naso FC, Marroni CA, Marroni NP. Melatonin restores zinc levels, activates the Keap1/Nrf2 pathway, and modulates endoplasmic reticular stress and HSP in rats with chronic hepatotoxicity. World J Gastrointest Pharmacol Ther 2022; 13(2) 11-22 |
|
Received |
|
2021-07-07 17:19 |
|
Peer-Review Started |
|
2021-07-07 17:25 |
|
To Make the First Decision |
|
|
|
Return for Revision |
|
2021-10-05 00:15 |
|
Revised |
|
2021-10-18 03:09 |
|
Second Decision |
|
2022-01-18 03:24 |
|
Accepted by Journal Editor-in-Chief |
|
|
|
Accepted by Company Editor-in-Chief |
|
2022-01-20 05:19 |
|
Articles in Press |
|
2022-01-20 05:19 |
|
Publication Fee Transferred |
|
|
|
Edit the Manuscript by Language Editor |
|
2022-01-04 11:21 |
|
Typeset the Manuscript |
|
2022-02-25 01:13 |
ISSN |
2150-5349 (online) |
Open Access |
This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/ |
Copyright |
©The Author(s) 2022. Published by Baishideng Publishing Group Inc. All rights reserved. |
Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
Website |
http://www.wjgnet.com |
© 2004-2024 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
California Corporate Number: 3537345